Phio Pharmaceuticals Corp. (Nasdaq: PHIO) has announced new data highlighting the role of its INTASYL siRNA gene silencing technology in improving immune cell efficacy against tumors. The data, presented at the 20th Annual Oligonucleotide Therapeutics Society (OTS) Meeting, demonstrates INTASYL's potential to enhance adoptive cell therapies and direct anti-tumor immune responses.
INTASYL Mechanism and Applications
INTASYL compounds offer precise targeting by silencing mRNA both intracellularly and extracellularly, significantly enhancing immune responses against cancer. They are effective as intratumoral injections and as excipients during immune cell expansion for adoptive cell therapy. INTASYL's efficient delivery system requires no special formulations to streamline siRNA delivery to target cells.
Preclinical Data Highlights
Several INTASYL compounds have shown promising preclinical results:
- PH-762: Silences PD-1, improving therapeutic efficacy in vivo.
- PH-894: Precisely silences BRD4 to enhance tumor cell immunogenicity and induce apoptosis.
- PH-804: Silencing TIGIT in NK cells enhances their activation, cytokine release, and target cell killing.
- PH-905: Silences CBLB, increasing NK cell cytotoxicity and proliferation.
About Phio Pharmaceuticals
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company focused on silencing specific genes using its proprietary INTASYL siRNA technology. INTASYL is primarily designed to enhance the ability of immune cells to kill tumor cells and can play a key role in improving adoptive cell therapy. Notably, INTASYL is the only self-delivering RNAi technology, in that does not require specialized formulations or drug delivery systems.
